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Perilous Passivity:  
The Insufficient Response to Antimicrobial Resistance 
INTRODUCTION 
 Antimicrobial resistance is a growing problem with a global scope. If left unaddressed, it 
threatens to diminish the effectiveness of antibiotic, antiviral, and antifungal medications. These 
medications, in tandem with vaccination, are largely responsible for the dramatic decline in the 
spread and mortality of infectious diseases worldwide since penicillin was first mass produced in 
1941. Thus, they are major contributing factors to one of the great achievements of modern 
humanity: the reduction of global childhood mortality in from between 30% and 50% in the 19th 
century to less than 0.5% today in industrialized nations.1 
 Repeated use of antimicrobial products causes antimicrobial resistance to develop. As 
antimicrobial-resistant traits emerge and spread to pathogens, they threaten the security from 
infectious diseases that antimicrobial medicines grant to society.  Therefore, to preserve the life-
saving power of these medicines, antimicrobial products must be used judiciously. However, in 
practice, they are used wantonly and without regard to the gradual, building effects of their 
overuse throughout the world. This is especially prevalent in commercial settings, as over 80% 
                                                     
1 Child Mortality, OUR WORLD IN DATA, https://ourworldindata.org/child-mortality (last visited 
Dec 14, 2018). 
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of antimicrobial products are used for agriculture.2 Nevertheless, it is similarly imperative to 
control their medical uses, as up to 50% of antibiotic prescriptions in the United States alone are 
either sub-optimal or entirely unnecessary.3 
 The tension between the long-term need to preserve the effectiveness of antimicrobial 
products and the immediate benefits of their use lies at the heart of the crisis surrounding 
resistance. To that end, the object of an effective regulatory scheme should be to deter the use of 
antimicrobials solely for profit or convenience, and to confine them to settings where their use is 
medically appropriate.  
Alongside regulation, research and development of novel drugs with antimicrobial effects 
that are not currently countered by resistance traits can be an effective tool in solving this crisis. 
However, no drug is immune to the process by which resistance develops; even novel drugs will 
in time become subject to the same limitations that current drugs face.4 Research and 
development alone, without simultaneous regulation of the use of currently effective drugs, 
cannot completely ameliorate the problem. 
Thus, governments throughout the world have a responsibility to regulate the use of 
antimicrobials in industry. Because the problem is of a global scale, there are global efforts to 
coordinate a response. Correspondingly, the United States government has taken steps to combat 
the problem within its own borders. Although totality of these efforts, both national and 
                                                     
2 The Overuse of Antibiotics in Food Animals Threatens Public Health, CONSUMERS 
UNION(2013), https://consumersunion.org/news/the-overuse-of-antibiotics-in-food-animals-
threatens-public-health-2/ (last visited Dec 14, 2018). 
3 TOM FRIEDEN, ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES, 2013(2013). 
4 Julian Davies & Dorothy Davies, Origins and Evolution of Antibiotic Resistance, 
3 MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS417–433 (2010), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937522/ (last visited Dec 14, 2018). 
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international, offer promising courses of action and demonstrate situational awareness, they are 
nevertheless insufficient to impede the rampant progression of antimicrobial resistance. In many 
areas, more stringent regulation is required to stop this threat to global public health. Without 
disrupting the monetary incentives that exist to use antimicrobial products in situations that are 
not medically necessary, the problem will not lessen. 
SCOPE AND MECHANICS 
 In order to accurately assess the appropriateness of measures taken to combat 
antimicrobial resistance, or suggest new ones, it is necessary to understand both the scope of the 
problem, and certain key scientific concepts that would affect the efficaciousness of any 
candidate policy. 
A. Scope of the Problem 
Antimicrobial resistance affects every nation on Earth, but it affects developing nations 
especially grievously. In Europe, antimicrobial-resistant pathogens are responsible for over 
25,000 fatalities and 2.0 million extra hospital days per year.5 In Thailand, they are responsible 
for 25,000 fatalities and 3.2 million extra hospital days per year.6 This is substantially larger 
relative to its population than the number of fatalities in Europe. Furthermore, that burden is felt 
substantially by the child and infant population. In India, antimicrobial-resistant pathogens are 
responsible for 58,000 infant deaths per year.7 This number exceeds the combined total fatalities 
in the examples of Europe and Thailand. Even relative to India’s larger population, the number 
                                                     
5 Antibiotic / Antimicrobial Resistance (AR / AMR), CENTERS FOR DISEASE CONTROL AND 
PREVENTION(2018), https://www.cdc.gov/drugresistance/about.html (last visited Dec 14, 2018). 
6 Id. 
7 Id. 
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of infants affected is disproportional. Furthermore, these numbers are growing as superfluous use 
of antimicrobials continues.8 
In the United States, antimicrobial-resistant pathogens are responsible for 23,000 fatalities 
and over 2.0 million extra hospital days.9 This puts additional logistical and financial strain on an 
already overburdened healthcare system that is dealing with a physician shortage, an uninsured 
population of 28.9 million,10 and an underinsured population of 41 million.11 In addition to these 
deaths and illnesses, the United States deals with 15,000 deaths and nearly 500,000 cases of 
Clostridium difficile per year.12 Because people taking antibiotics are 7 to 10 times more likely to 
contract C. difficile,13 this is yet another compounding effect of the overuse of antibiotics by 
medical professionals. Similar to the worldwide trend, these numbers form an increasing trend of 
complications that arise from antimicrobial resistance.14 
B. Causes of and Contributors to the Problem 
There are two main forces that contribute to the development of antimicrobial resistance: 
medicine and agriculture. Each of these two causes carries its own set of challenges that must be 
overcome to effectively combat the problem. Despite this distinction, however, the two share 
common ground. Both have entrenched systems that monetarily incentivize the use of antibiotics 
                                                     
8 Id. 
9 Id. 
10 National Center for Health Statistics, CENTERS FOR DISEASE CONTROL AND 
PREVENTION(2017), https://www.cdc.gov/nchs/fastats/health-insurance.htm (last visited Dec 14, 
2018). 
11 Sara R. Collins, Munira Z. Gunja & Michelle M. Doty, HOW WELL DOES INSURANCE 
COVERAGE PROTECT CONSUMERS FROM HEALTH CARE COSTSCOMMONWEALTH FUND, 
https://www.commonwealthfund.org/sites/default/files/documents/___media_files_publications_
issue_brief_2017_oct_collins_underinsured_biennial_ib.pdf (last visited Dec 14, 2018). 
12 CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities. Atlanta, GA: US 
Department of Health and Human Services, CDC; 2017. 
13 Id. 
14 Id. 
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when not medically necessary. Both are in fact parts of a larger, interconnected network of 
associations that spreads reserves of resistant traits throughout the microbial populations of the 
country: 
Figure 115: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1 demonstrates that superfluous use of antimicrobial products anywhere 
contributes to the problem of antimicrobial resistance everywhere. It is impossible to solve this 
crisis by focusing solely on one area where a reserve of antimicrobial resistance exists. Because 
of the communicability of resistance traits between separate populations of microbes, stopping, 
                                                     
15 Davies & Davies, supra note 4. 
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for example, only the medical overuse of antibiotics without even considering the other reserves 
of resistance would not impede the exacerbation of the problem overall. 
C. Some Essential Scientific Concepts 
It is difficult to understand the effects of policy regarding antimicrobial resistance without 
understanding certain conceptual elements of the mechanics of its development and spread. 
Chief among these concepts is selective pressure, a term in evolutionary biology that 
refers to one of the driving forces of evolution by natural selection, or the idea that organisms 
gradually change over time based on which organisms have traits that make them more likely to 
survive and reproduce.16 When a factor causes some members of a population to be more likely 
to survive and reproduce than other members of the same population, evolutionary biologists call 
that factor a selective pressure.17 For example, limited access to water is a selective pressure that 
shaped the evolution of flora and fauna in deserts around the world. Cacti exist in deserts in large 
part because plants that are best at storing and economizing water are more likely to survive and 
reproduce in deserts than plants that are not. 
In the case of antimicrobial resistance, every time an antimicrobial product is used, it 
applies an extremely heavy selective pressure to the population of microbes it comes into contact 
with.18 It kills the vast majority of them, and the few survivors are far more likely to have traits 
that resist the antimicrobial effects. These survivors repopulate, creating an entirely new 
generation of bacteria, all of which share the increased resistance of the generation before it.19 A 
single application of selective pressure has a negligible effect, but the timeframe for a generation 
                                                     
16 Glossary, ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS, 
http://emerald.tufts.edu/med/apua/about_issue/glossary.shtml (last visited Dec 14, 2018). 
17 Id. 
18 Id. 
19 Id. 
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of bacteria can be a matter of minutes. The repeated application of this heavy selective pressure 
causes the buildup of resistant traits over time and can render some populations of bacteria 
resistant to many types of antibiotics. For example, S. Aureus exhibited resistance to methicillin 
as early as 1962, a mere 3 years after it was first exposed to the drug.20 In the context of  
evolutionary timescales, antimicrobial resistance develops blindingly fast. 
The final concept that must be understood in order to contextualize policy is horizontal 
gene transfer. Many organisms, such as humans and animals, can only pass genetic information 
from parent to offspring, and only within the same species. This is vertical gene transfer. 
Bacteria, however, have an array of methods to pass genetic information from one member of a 
contemporary generation to another, and between species. This concept is paramount because it 
means that antibiotic resistant traits are dangerous in all species of bacteria, not just the ones that 
cause disease.21 When a patients or livestock take antibiotics, it subjects all susceptible bacteria 
within them to the same selective pressure. Over time, the resultant traits spread throughout the 
chain of commerce and can extend even to the farthest reaches of the world. 
GLOBAL RESPONSE 
 Because antimicrobial resistance is a global problem, there necessarily exists 
international cooperation in combatting it. Due to the phenomenon of globalization, national 
action plans are not sufficient to combat the problem by themselves.22 Microbes move freely 
about the world, unhindered by borders, and cross oceans in the process of global trade. The 
                                                     
20 Id. 
21 See supra note 16. 
22 David P. Fidler, LEGAL ISSUES ASSOCIATED WITH ANTIMICROBIAL DRUG RESISTANCE - 
VOLUME 4, NUMBER 2-JUNE 1998 - EMERGING INFECTIOUS DISEASES JOURNAL – CDC CENTERS 
FOR DISEASE CONTROL AND PREVENTION(2010), https://wwwnc.cdc.gov/eid/article/4/2/98-
0204_article (last visited Dec 14, 2018). 
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central coordinator of international efforts to combat antimicrobial resistance is the United 
Nations (UN). Most initiatives and policies occur through the World Health Organization 
(WHO), but some activity also that takes place through the Food and Agriculture Organization 
(FAO), the Organization for Animal Health (OIE), the office of the Secretary General and the 
General Assembly. 
A. UN General Assembly 
In 2015, the UN General Assembly passed Resolution 70/183, which, among other 
things, called upon heads of state to hold a meeting to address the growing problem of 
antimicrobial resistance.23 Included in this resolution is the globally unified recognition that 
“antimicrobial resistance threatens the sustainability of the public health response to many 
communicable diseases, including tuberculosis, malaria and HIV/AIDS.”24 Particularly notable 
here is the mention of malaria. Although its localized eradication has eliminated it as a threat in 
the United States, it is nevertheless one of the deadliest infectious diseases in the world, claiming 
an annual toll of 212 million infections and 429,000 fatalities.25 The fact that the protozoan 
parasite that causes the disease is developing antimicrobial resistance has a particularly 
devastating impact on developing nations.26 
As a result of the 2016 meeting of the heads of state called for by Resolution 70/183, 
member nations passed Draft Declaration 16-16108. This draft declaration contained another 
                                                     
23 General Assembly Resolution 70/183, Global health and foreign policy: strengthening the 
management of international health crises, A/RES/70/183 (17 December 2015), available from 
https://undocs.org/A/RES/70/183. 
24 Id. 
25 Malaria Drug Resistance, IVERMECTIN EXPOSURE IN SMALL CHILDREN STUDY GROUP | 
WORLDWIDE ANTIMALARIAL RESISTANCE NETWORK(2014), http://www.wwarn.org/about-
us/malaria-drug-resistance (last visited Dec 14, 2018). 
26 Id. 
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affirmation of global consensus regarding the critical nature of the crisis of antimicrobial 
resistance, this time from a gathering of many of the world’s heads of state. It also contained the 
resolution of the member heads of state to each form their own national action plans for the 
purpose of combatting the crisis.27 Other notable language from the declaration includes the 
recognition that “achievements of the twentieth century are being gravely challenged, in 
particular: the reduction in illness and death from infectious diseases achieved through social and 
economic development; access to health services and to quality, safe, efficacious and affordable 
medicines…”28 This language accurately captures the severity of the problem. 
The totality of the actions of the UN General Assembly consistently display situational 
awareness and an appropriate tone. They rightly account for the scientific consensus regarding 
the gravity of the problem and demonstrate a global commitment to solving it. However, they 
contain no mechanism to enforce consequences for any nation that fails to follow the resolution 
and draft declaration. If a member nation were to undergo a sudden, drastic change in 
governmental leadership as, for example, the United States did shortly after the passage of the 
draft declaration on September 21, 2016, nothing could compel it to uphold the promises of its 
former head of state. Furthermore, if a member nation were to fail to effectively combat the 
problem due to persistent monetary incentives to use antimicrobial products in situations that are 
not medically necessary, then the international community is similarly left without recourse. 
B. Office of the UN Secretary General 
                                                     
27 United Nations, Draft Declaratoin 16-16108, Draft political declaration of the high-level 
meeting of the General Assembly on antimicrobial resistance (21 Sepbember 2016), available 
from un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-
Draft-Political-Declaration-1616108E.pdf. 
28 Id. 
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Another action taken by the UN to facilitate the worldwide fight against antimicrobial 
resistance is the formation of the Interagency Coordination Group (IACG) by the Secretary 
General. The purpose of the IACG is to effectuate communication and collaboration between the 
several UN organizations that have separate interests and responsibilities in controlling the 
antimicrobial resistance crisis.29 These organizations include the WHO, the FAO, and the OIE.30  
Although there are no affirmative plans put forward by the IACG, it is worthy of mention 
because it accounts for the interconnectivity of reserves of antimicrobial-resistant traits discussed 
earlier. Only by ensuring that all sectors of the global economy that contribute to the problem are 
fighting it effectively can the problem be sufficiently mitigated. 
An example of cross-organizational cooperation can be found in the World Antibiotics 
Awareness Week, which takes place every November. All three organizations have observance 
programs which include public events across the globe and ways for individuals and 
organizations to get involved.31 Lack of general public awareness is one of the most difficult 
challenges that the effort to combat antimicrobial resistance faces. Much like with global climate 
change before it was popularized, the low general awareness makes it difficult to galvanize 
action. The fact that there is a synchronized effort to spread the word across the world is critical 
to response efforts across the globe. 
C. WHO  
                                                     
29 UN Interagency Coordination Group on Antimicrobial Resistance, WORLD HEALTH 
ORGANIZATION(2018), https://www.who.int/antimicrobial-resistance/interagency-coordination-
group/en/ (last visited Dec 14, 2018). 
30 Id. 
31 WORLD HEALTH ORGANIZATION, http://www.who.int/who-campaigns/world-antibiotic-
awareness-week (last visited Dec 14, 2018). 
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The WHO is one of the three UN organizations with a primary role in the response to 
antimicrobial resistance. It has a main program that is a part of the effort to combat the crisis. 
The WHO’s Global Action Plan (GAP) is a five-pronged strategy for how to proceed in 
the global response to antimicrobial resistance. The five objectives of the plan are to: (1) improve 
awareness and understanding of antimicrobial resistance through effective communication, 
education, and training; (2) strengthen the knowledge and evidence base through surveillance 
and research; (3) reduce the incidence of infection through effective sanitation, hygiene, and 
infection prevention measures; (4) optimize the use of antimicrobial medicines in human and 
animal health; and (5) develop the economic case for sustainable investment that takes account 
of the needs of all countries, and increase investment in new medicines, diagnostic tools, 
vaccines and other interventions.32 
All of the WHO’s actions in response to antimicrobial resistance are guided by the prongs 
of the GAP. World Antibiotic Awareness Week is an example of the first prong. In accordance 
with the second prong, the WHO has proposed that there be a recognized international standard 
for the collection of data and antimicrobial resistance in human health, and a global form for the 
rapid sharing of information about the crisis, both of which currently do not exist.33 In 
accordance with the third prong, the WHO has advocated for the widespread use of 
immunizations and vaccinations to prevent incidence of infection.34 In accordance with the 
fourth prong, the WHO has resolved that the scientific consensus supports the conclusion that the 
                                                     
32 Global Action Plan on Antibiotic Resistance (2015), available from 
http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf (last 
visited Dec 14, 2018). 
33 Id. at 9. 
34 Id. 
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massive volume of antimicrobials being used worldwide is driving the problem of resistance.35 In 
accordance with the fifth prong, the WHO has suggested that novel drugs and screening 
technology be made available and affordable, so as to satisfy the needs of all member nations.36 
The GAP concludes by setting a framework for its implementation in which it urges member 
nations to develop similar plans and apply them nationally. 
Overall, the GAP, like many of the other international efforts to coordinate a response to 
antimicrobial resistance, shows apt cognizance of the issues and suggests reasonable and 
effective measures to combat the problem. However, also like its counterpart international 
efforts, it fails to recognize the immense difficulty that member nations will face in 
implementing these plans despite the entrenched monetary incentives to use antimicrobial 
products when not medically necessary. 
D. FAO and OIE 
The FAO and OIE have each promulgated similar four-pronged strategies for how their 
respective domains will proceed in the global response. The FAO’s plan is to: (1) improve 
awareness on AMR and related threats; (2) develop capacity for surveillance and monitoring of 
AMR and AMU (antimicrobial use) in food and agriculture; (3) strengthen governance related to 
AMU and AMR in food and agriculture; and (4) promote good practices in food and agricultural 
systems and the prudent use of antimicrobials.37 
Again, the familiar themes of awareness and monitoring, both fundamental elements that 
need improvement, are mentioned first. The third prong, however, deviates from the other plans 
                                                     
35 Id. at 10. 
36 Id. at 11. 
37 FAO's role | www.fao.org, INTERNATIONAL RICE COMMISSION NEWSLETTER VOL. 48, 
http://www.fao.org/antimicrobial-resistance/background/fao-role/en/ (last visited Dec 14, 2018). 
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in a way that is encouraging. When the plan says to, “strengthen governance,” it advocates for 
member governments to compel their food and agriculture industries to use antimicrobials more 
judiciously. Despite its lack of binding authority, this plan recognizes that a large obstacle in its 
implementation is the ability and willingness of member governments to compel industry to 
make monetary sacrifices to solve a long-term public health problem. 
The OIE’s plan is identical on the first three prongs, but the fourth is to implement 
international standards. This is a sensible inclusion because the existence of international 
standards for the prudent use of antimicrobials will streamline the process of global advocacy to 
curtail their rampant overuse. 
When viewed as a whole, the coordinated international response to antimicrobial 
resistance, though unequivocally moving in the right direction, is insufficient on its own to 
remove the problem as a threat. Although programs like WHO’s Global Antimicrobial 
Surveillance System (GLASS), a means to achieve the second prong of the GAP by establishing 
an internationally accessible and comprehensive surveillance system for the detection of new 
antimicrobial resistant traits,38 create real positive change, that change is not enough without 
member nations curbing the overuse of antimicrobial products. 
DOMESTIC RESPONSE 
 The United States government has its own set of plans and has taken its own set of 
actions to deal with the antimicrobial resistance crisis within its borders. These include both 
regulations with binding authority and industrial suggestions without any means of enforcement. 
The plans and actions are promulgated both by government agencies and by industry leaders. 
                                                     
38 Call for participation: Global Antimicrobial Resistance Surveillance System 
(GLASS), WORLD HEALTH ORGANIZATION(2016), 
http://www.who.int/drugresistance/surveillance/glass-enrolment/en/ (last visited Dec 14, 2018). 
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A. CDC 
The Center for Disease Control (CDC) has both implemented programs and promulgated 
plans for dealing with antimicrobial resistance domestically. Much of what it does nationally is 
analogous to what the WHO does internationally. 
i. Surveillance 
The CDC participates in partnership with the FDA in the National Antimicrobial 
Resistance Monitoring System (NARMS).39 In many ways, NARMS is the domestic equivalent 
of GLASS. It monitors and records emergent antimicrobial traits and their presence in pathogens. 
This, like all surveillance, is an effective tool in the fight to mitigate the effects of antimicrobial 
resistance, but it cannot remove the presence of selective pressure. As long as antimicrobial 
products are still overused, the problem will continue to grow. 
Additionally, the CDC has promulgated a list of response tiers to prioritize the threats 
posed by the many antimicrobial-resistant pathogens that are on record. The tiers are: (1) 
organisms whose mechanisms of resistance are novel to the United States, or that are pan-
resistant (e.g. Vanomycin-resistant S. Aureus [VRSA])40; (2) multi-drug resistant organisms 
(MDROs) that are typically found in healthcare settings, but not generally in the surrounding 
region;41 and (3) MDROs that have already been identified and established in the United States.42 
ii. Five-point plan 
                                                     
39 National Antimicrobial Resistance Monitoring System for Enteric Bacteria 
(NARMS), CENTERS FOR DISEASE CONTROL AND PREVENTION(2018), 
https://www.cdc.gov/narms/about/index.html (last visited Dec 14, 2018). 
40 Healthcare-associated Infections, CENTERS FOR DISEASE CONTROL AND PREVENTION(2018), 
https://www.cdc.gov/hai/containment/guidelines.html (last visited Dec 14, 2018). 
41 Id. 
42 Id. 
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The CDC, in compliance with the WHO’s GAP, has promulgated its own five-point plan 
to combat antimicrobial resistance. The prongs are: (1) awareness and education; (2) 
surveillance; (3) infection prevention and control; (4) optimization of use; and (5) R&D and 
investment. 
These tiers and plans are effective to facilitate the containment of already-existing 
MDROs, but like the surveillance programs, do not effectively deal with the problem of selective 
pressure, and are not enough on their own. Point 4, optimization of use, would account for the 
necessity for judicious use of antimicrobial products, but without a means to compel industry to 
comply, it is ineffective.  
The CDC has the power to promulgate regulations, but it is not the ideal government 
agency to pass regulations banning the overuse of antimicrobial products. Although it has the 
power the power to enact regulations to control the spread of infectious diseases,43 this power is, 
with one exception, limited to the function of quarantine powers in times of emergency and war. 
That exception is that the Surgeon General may, with the approval of the secretary, make and 
enforce regulations that are, “necessary to prevent the introduction, transmission, or spread of 
communicable diseases from foreign countries into the States or possessions, or from one State 
or possession into any other State or possession.”44  
resistance, which is rather the development of resistant traits in already extant diseases. 
B. FDA 
                                                     
43 See 42 U.S.C. §264. 
44 42 U.S.C. §264(a). 
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The Food and Drug Administration (FDA) unquestionably has the authority to regulate, 
ban, or otherwise limit the use of antimicrobial chemicals because they are drugs. In their hands 
is the power to compel industry to act. 
i. Antibacterial Soap  
One decisive action that the FDA has taken to secure the judicious use of antimicrobial 
products and combat antimicrobial resistance was ban the sale soaps that use certain antibacterial 
compounds, most prominently triclosan.45 These products, advertised as killing bacteria, are not 
more effective at cleaning than non-bactericidal soaps. This is because soap cleans by 
emulsifying the germs on surfaces and making them water soluble, allowing water to physically 
remove them from a surface. The needless addition of a bactericidal effect does nothing salutary, 
and in fact applies selective pressure to bacteria that are exposed to it, contributing to 
antimicrobial resistance. 
However, the final rule that banned these antibacterial soaps is imperfect. It only banned 
a limited list of antibacterial chemicals, not bactericidal effects in general.46 Thus, antibacterial 
soaps using chemicals that are not on the list may still be sold, and industrial chemists are free to 
develop more chemicals for use in soaps that would kill bacteria. In this way, antibacterial soap 
maintains a limited presence in the market, and the label “kills 99.9% of germs and bacteria” 
may still appeal to the general consumer. 
ii. Agricultural Industry 
Antibiotic use in the agricultural industry, comprising over 80% of the world’s antibiotic 
use, is different from ordinary medical use. Antibiotics are used in limited capacity on livestock 
                                                     
45 81 FR 61106 
46 Id. 
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to preemptively prevent or reactively treat diseases, but their main use is that when they are 
added to livestock’s feed, they improve the feed conversion ratio of the livestock.47 The feed 
conversion ratio is the ratio to the cost to feed an animal to the revenue yielded by selling its 
products. In other words, antibiotics make livestock grow larger for less money. In fact, they 
increase the feed conversion ratio between 3% and 9%, and the total size of livestock between 
2% and 10%.48 Considering the amount of meat that is produced in the United States annually, 
antibiotics account for a significant profit. 
To combat the crisis of antibiotic resistance, the FDA has promulgated Guidelines for 
Industry (GFI), to communicate the best practices and the agency’s current thinking on topics of 
interest. The two GFIs that address antibiotic use in agriculture are GFI #20949 and GFI #213.50 
GFI #209 addresses the problem that superfluous use of antibiotics in animal feed is 
wildly exacerbating the problem of antimicrobial resistance. This occurs because of horizontal 
gene transfer; the danger does not particularly lie in the pathogenic bacteria that get refined by 
the rampant use of antibiotics, but the development of resistance traits in non-pathogenic bacteria 
that are then transferred to pathogenic bacteria as the meat from the livestock travels down the 
stream of commerce. This GFI articulates a progressive and solution-oriented position by the 
                                                     
47 Overview of Growth Promotants and Production Enhancers - Pharmacology, MERCK 
VETERINARY MANUAL, https://www.merckvetmanual.com/pharmacology/growth-promotants-
and-production-enhancers/overview-of-growth-promotants-and-production-enhancers (last 
visited Dec 14, 2018). 
48 Id. 
49 Guidance for Industry #209, the Judicious Use of Medically Important 
Antimicrobial Drugs in Food-Producing Animals 
50 Guidance for Industry #213, New Animal Drugs and New Animal Drug Combination Products 
Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: 
Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI 
#209. 
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FDA, stating, “[the] FDA is providing a framework for the voluntary adoption of practices to 
ensure the appropriate or judicious use of medically important antimicrobial drugs in food-
producing animals.”51 Furthermore, to achieve this end, the FDA prescribes two main modes of 
action, which are:  “(1) limiting medically important antimicrobial drugs to uses in food-
producing animals that are considered necessary for assuring animal health; and (2) limiting such 
drugs to uses in food-producing animals that include veterinary oversight or consultation.”52 
Although the distinction of “medically important” drugs, defined in a footnote as drugs 
“important for therapeutic use in humans,”53 allows compliant companies to curtail their use of 
antibiotics while ignoring the underlying problem posed by horizontal gene transfer, any 
decrease in the use of antibiotics in farming is a massive victory toward impeding antimicrobial 
resistance. 
GFI #213 expands on some of the restrictions set forth in GFI #209 while loosening. It 
states that its purpose is to help phase out the use of “medically important” drugs in livestock for 
non-medical purposes entirely.54 It expands a level of oversight for certain drugs whereby 
compliant companies would need to obtain a Veterinary Feed Directive (VFD) in order to infuse 
animal feed with antibiotics, certifying that it is medically necessary.55 A VFD is less stringent of 
a barrier to obtaining antibiotics than a prescription is.56 It moves many drugs that were once 
prescription-only into the category of VFD, thus expanding access to those drugs. However, it 
                                                     
51 Supra note 44 at 3. 
52 Id. 
53 Id. 
54 Supra note 45 at 4. 
55 Id. 
56 Id. 
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also moves many drugs that were once available over the counter to VFD, thus limiting access to 
those drugs.57 
Overall, the liberality with which a veterinarian may issue a VFD is concerning, 
especially considering the tendency of companies form working relationships with veterinarians. 
Additionally, the retention of the label “medically important” to the drugs being phased out 
leaves the same problems that were present in GFI #209 unresolved. 
Accompanying the continued permissiveness of antibiotic use in compliant companies, 
the GFI’s have one additional fatal flaw. In both GFI #209 and GFI #213, there is a block of text 
just before the introduction that states that the entire document is nonbinding.58 
This means that compliance with FDA GFI’s is entirely voluntary. Should a company 
wish to simply use antibiotics at its own will to maximize profits, it is free to do so. Thus, using 
antibiotics in animal feed is still a common practice to this day. Some industry leaders, such as 
Tyson, offer antibiotic-free options for beef and pork at a markup alongside their antibiotic-fed 
options.59 Although the argument can be made that allowing consumers to vote with their wallets 
leaves an avenue to affect change at the supermarket, most people just want an affordable cut of 
meat, which limits the effect that a conscientious bloc of consumers can have. Rather, the 
antibiotic-free label is a token offering, an excuse to charge some conscientious consumers or 
misguided health-conscious consumers a markup, standing brazenly in defiance of the global 
imperative to halt the superfluous use of antimicrobial drugs. 
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C. Medical Industry 
The remainder of global antimicrobial use is for medical purposes. Unfortunately, the 
over-prescription of antibiotics is a rampant problem, especially in the developed world. There 
are many causes for this worldwide overuse, ranging from misperceptions about the role of 
physicians to perverse incentive structures for the physicians themselves. 
In the United States, approximately 1 in every 3 prescriptions for a course of antibiotics is 
unnecessary.60 The total amount of inappropriate use of antibiotics, including inappropriate 
selection, dosing, and duration, approaches 1 in every 2 uses.61  
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The volume of outpatient prescriptions in an area can affect local resistance patterns.63 
Figure 2 demonstrates that there is a high variance of prescription volume among the states. 
However, every state still grievously over-prescribes.64 
Furthermore, the bulk of the over-prescription problem occurs in outpatient settings. Over 
60% of all antibiotic prescriptions in the United States occur in outpatient facilities.65 Between 
80% and 90% of the total volume of antibiotics consumed by humans in the United states occur 
as a result of prescriptions in an outpatient setting.66 
Respiratory infections are the most common causes of antibiotic prescriptions.67 
However, the majority of respiratory infections are not caused by bacteria.68 This disparity is a 
microcosm of the larger problem of antibiotic over-prescription. 
Among physicians, there have been numerous initiatives to promote antibiotic 
stewardship. For example, the American Medical Association (AMA) has spearheaded several 
plans to reduce antibiotic prescription rates. For example, in several clinics, AMA doctors 
displayed an open letter, written in large font and in eighth grade-level English, about the 
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importance of antibiotic stewardship. Clinics that displayed this letter saw average drops of 
around 9% in antibiotic prescription rates for respiratory infections.69 
The AMA is also experimenting with more overt methods to reduce prescription rates. At 
some clinics, physicians that enter a diagnosis of a respiratory infection into a patient’s electronic 
health record (EHR), accompanied by a prescription for antibiotics, must fill in an additional line 
of text stating the justification for the prescription. If no justification is entered, the EHR displays 
“NO JUSTIFICATION FOR PRESCRIBING ANTIBIOTIC.”70 Additionally physicians at 
clinics are ranked by their antibiotic prescription rates, giving a sense of peer accountability.71 
Clinics that implement these experimental methods have seen a drop of 16%-18% in prescription 
rates.72 These simple methods of holding physicians to some rudimentary form of accountability 
make tangible progress in curbing antibiotic prescription rates. However, none of them have yet 
seen widespread adaptation.73 
Furthermore, the CDC makes efforts to communicate with physicians about the 
importance of antibiotic stewardship. For example, it has promulgated a table of 
recommendations about how to determine whether it is appropriate to prescribe antibiotics with 
certain common conditions, as well listing the proper course of treatment in situations when 
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antibiotics are not appropriate.74 Additionally, it offers a course on antibiotic stewardship for 
continuing education credits.75 
Although these efforts to stop the over-prescription problem in the United States are 
admirable, they are insufficient. What is missing from the larger picture of reducing prescription 
rates is any binding provision. As it stands, there is no enforced negative consequence for 
physicians who unnecessarily prescribe antibiotics for illnesses that do not in fact require them. 
Rather, there are perverse incentives for physicians to continue to prescribe antibiotics at 
current rates. First, physicians are pressured by patients who have expectations about how their 
treatment will go.76 Specifically, patients who present with an illness expect to be given a 
medication that fixes their illness.77 However, there are many illnesses with no simple 
pharmaceutical cures. Thus, physicians often motivated by the demand to meet consumer 
expectations when they prescribe antibiotics when medically unnecessary, and when the correct 
treatment is to wait for the illness to expire while treating ancillary symptoms.78 
Additionally, in outpatient settings, physicians often have a limited time to meet with 
patients. Often, that time is not enough to diagnose an illness and formulate a treatment plan. 
Thus, physicians can rely upon prescribing antibiotics as a heuristic method of dealing with 
problems.79 This problem is confounded even more by the fact that viral and bacterial infections 
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often present similar symptoms. In these cases, prescribing antibiotics is preferable to the risk 
physicians incur by not prescribing them.80 Often, it is more time-efficient for physicians just to 
prescribe antibiotics rather than to lengthily explain why antibiotics are not required.81 These 
efficiencies add up to significant amounts over time. Finally, pharmaceutical companies are 
permitted to advertise to physicians through representatives. The interactions between the 
representatives and the physicians, often involving gifts, influences physicians’ prescribing 
habits.82 
D. Research Efforts 
There have been significant efforts to combat the problem of antimicrobial resistance 
through researching innovative solutions. One method that researchers use to combat the 
problem is to develop new antimicrobials that are not yet resisted.83 These can be effective 
means of slowing the problem. However, creating new antimicrobial drugs cannot stop the 
process of selective pressure, or remove the bacterial trait of horizontal gene transfer.84 New 
drugs cannot be a permanent solution to antimicrobial resistance, but they can slow it 
significantly.85 
Phage therapy is a second avenue of research that, though underdeveloped relative to 
antimicrobials, may provide promising results in the future.86 It functions by combatting bacterial 
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infections using bacteriophages, or viruses that infect bacteria.87 These phages are harmless to 
humans and highly specific infectors of their bacterial targets.88 Through controlled introduction 
to an infected patient, phage therapy may one day be able to defeat bacterial infection as 
effectively as antibiotics would.89 The bacteria would not stop evolving, and would develop 
resistances to bacteriophage infection the same way they develop resistances to antibiotics.90 
However, there is evidence that suggests that when bacteria develop resistance to bacteriophages, 
they sacrifice resistances to antibiotics, and when they develop resistances to antibiotics, they 
sacrifice resistances to bacteriophages.91 Thus, phage therapy, once developed, remains a 
promising hope to bringing a permanent end to the threat of antimicrobial resistance in the 
future. 
CONCLUSION 
 Antimicrobial resistance is a long-term danger with potentially disastrous results. If 
current levels of antimicrobial product use do not drop, the phenomenon threatens to undo some 
of the landmark achievements of human development, such as the lowered deaths from 
infectious diseases and the reduction in infant and child mortality. 
 Global efforts to impede its progression focus primarily on surveillance, monitoring, the 
development of new drugs, and the spreading of awareness. These are effective tools, and the 
world is objectively better off as a result of these efforts. However, they paint an incomplete 
picture of the solution to antimicrobial resistance. 
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 Selective pressure is a natural law that acts constantly on every organism alive. It, 
compounded with the bacterial phenomenon of horizontal gene transfer, indicate that there can 
be no sufficient solution to antimicrobial resistance without limiting the use of antimicrobial 
products to situations where they are medically necessary. 
 The rampant over-prescription of antimicrobial drugs, combined with the commonplace 
use of antibiotics in animal feed, accelerate the problem of antimicrobial resistance more than the 
current combined totality domestic and global efforts are able to slow it down. Therefore, the 
response to the problem is insufficient. Only by compelling physicians and agricultural 
companies to cease the superfluous use of antimicrobial products can a response to the crisis be 
effective enough to mitigate the damage caused by the rapid global development of antimicrobial 
resistance. 
 However, there remains hope that through continued research, humanity may develop a 
permanent solution to the problem. The continued development of new drugs, and promising 
research into the relatively novel field of phage therapy, shine as beacons of hope that in the long 
term, antimicrobial resistance is solvable. 
